Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.39% during the week of January 19-23, 2026, ranking 27th among 31 sectors, while outperforming the CSI 300 index by 0.23 percentage points. The current PE valuation for the sector stands at 30.27 times, which is at the historical median level, with a valuation premium of 126% compared to the CSI 300 [5][16][23]. - The top-performing sub-sectors during this period were pharmaceutical commerce (4.26%), traditional Chinese medicine II (0.89%), and medical devices (0.30%) [5][14]. - A total of 330 stocks (69.62%) in the sector rose, while 137 stocks (28.90%) fell. The top five gainers included *ST Changyao (70.37%), Hualan Biological Engineering (32.21%), and Kangzhong Medical (25.47%) [5][31]. Market Performance - The pharmaceutical and biotechnology sector's performance for the year-to-date shows an increase of 6.66%, ranking 16th among 31 sectors and outperforming the CSI 300 index by 5.10 percentage points. The sub-sectors that achieved growth included medical services (13.53%), medical devices (9.50%), and pharmaceutical commerce (7.77%) [16][22]. - The PE valuations for various sub-sectors are as follows: medical devices (36.13), chemical pharmaceuticals (34.34), biological products (33.61), medical services (32.89), traditional Chinese medicine II (22.22), and pharmaceutical commerce (17.16) [23][30]. Industry News - On January 22, 2026, nine government departments, including the Ministry of Commerce and the National Health Commission, jointly issued guidelines aimed at promoting high-quality development in the pharmaceutical retail industry. The policy focuses on six key areas, emphasizing a combination of government guidance and market leadership to enhance professional and intensive development within the industry [6][33]. - The guidelines encourage the integration of pharmaceutical services, improvement of pharmacy service capabilities, and the promotion of prescription circulation and medical insurance outpatient coordination services. They also support the establishment of a commercial insurance payment system and the expansion of health management services [6][33][34]. Investment Recommendations - The report suggests a cautious approach to the pharmaceutical and biotechnology sector, highlighting the recent weak performance of previously popular stocks. It emphasizes the importance of the new guidelines in transforming the industry from a "single drug sales" model to a "health service" model [6][34]. - The report recommends focusing on leading chain pharmacies with strong financial capabilities and merger integration abilities, as well as innovative drug chains, medical devices, healthcare services, and second-class vaccines for potential investment opportunities [6][34][7].

Core Insights - The JPMorgan Global Healthcare Conference serves as a significant platform for the biopharmaceutical industry, influencing capital flows and industry dynamics for the year ahead [1] - This year's conference highlighted the increasing presence of Chinese biotech companies, marking a shift from being mere spectators to key players in the global market [2][3] Group 1: Chinese Biotech Companies - Seven Chinese companies, including WuXi AppTec and BeiGene, presented on the main stage, with an additional 17 companies showcasing in the Asia-Pacific session [2] - The transformation of Chinese companies from the periphery to the center of the conference reflects their substantial innovation value, evidenced by numerous licensing deals announced during the event [3] Group 2: Licensing Deals and Collaborations - Notable licensing agreements included a $650 million upfront payment from AbbVie to Rongchang Biopharma for the global rights to its PD-1/VEGF dual-specific antibody, with a total potential deal value of up to $5.6 billion [3] - Other significant collaborations involved Zhongsheng Peptide and Sai Shen Pharmaceutical partnering with Novartis, with the latter's deal valued at approximately $1.665 billion [3] Group 3: MNCs and Market Dynamics - The cautious approach of multinational corporations (MNCs) towards acquisitions is driven by the impending "patent cliff," with over $320 billion in market potential products set to lose patent protection in the next decade [3][5] - MNCs are increasingly favoring "asset-based acquisitions" over full company buyouts, allowing them to efficiently acquire core assets without the burdens of integrating entire companies [4] Group 4: AI in Drug Development - AI's integration into drug development emerged as a central theme, with Eli Lilly and NVIDIA announcing a partnership to establish a $1 billion AI innovation lab aimed at addressing long-standing challenges in the pharmaceutical industry [5][6] - The acquisition of Modella AI by AstraZeneca further emphasizes the growing importance of AI in enhancing drug discovery and clinical development processes [6] Group 5: Future Outlook - The 2026 JPM conference is expected to reflect a new paradigm where Chinese innovation becomes essential, and AI evolves from a supportive tool to a foundational infrastructure in drug development [8][9]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a downward trend below the average [4][19] - The top three sub-industries by PE are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction of 2.125 billion yuan in shareholder holdings, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Review - The report highlights significant developments in the pharmaceutical retail sector, emphasizing the need for transformation from traditional drug sales to comprehensive health services [24][25] - The Ministry of Commerce and other departments issued opinions to promote high-quality development in the pharmaceutical retail industry, projecting a market size increase from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a growth of 22.4% [24][25] - The report also discusses the approval of new drugs and treatments, including the PD-1/VEGF bispecific antibody RC148 by Rongchang Biopharmaceuticals, which has a potential total payment of up to 4.95 billion USD [7][50] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation from high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADC, bispecific antibodies, and siRNA therapies [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 1.07%, ranking 26th among 31 primary industries, outperforming the CSI 300 index which fell by 1.19% [4][15] - The valuation of the pharmaceutical and biotechnology industry as of January 23, 2026, is a PE (TTM overall method, excluding negative values) of 30.31x, down from 30.56x in the previous period, indicating a decline in valuation below the average [4][19] - The top three sub-industries by PE (TTM overall method, excluding negative values) are vaccines (47.34x), hospitals (44.94x), and other medical services (40.38x), while the lowest valuation is in pharmaceutical circulation (15.31x) [4][19] - During the reporting period, 34 listed companies in the pharmaceutical and biotechnology sector saw a net reduction in shareholder holdings amounting to 2.125 billion yuan, with 2 companies increasing holdings by 63 million yuan and 32 companies reducing holdings by 2.189 billion yuan [4] Industry Trends - The 2026 JPM Conference highlighted Chinese innovative drugs as a global focus, with several Chinese companies showcasing advancements in PD-1/VEGF bispecific antibodies, ADCs, and cell therapies [7] - The report suggests focusing on innovative pharmaceutical companies with differentiated pipelines that have received validation through high-quality collaborations with multinational pharmaceutical companies, particularly in key areas such as ADCs, bispecific antibodies, and siRNA therapies [7] Important Industry News - The Ministry of Commerce and eight other departments issued opinions on promoting high-quality development in the drug retail industry, projecting a growth in the drug circulation market from 2.41 trillion yuan in 2020 to 2.95 trillion yuan by 2024, a 22.4% increase [24] - The National Healthcare Security Administration released guidelines for pricing projects related to surgical and treatment auxiliary operations, aiming to standardize and promote the use of advanced medical technologies [27][28] - Notable approvals include Daiichi Sankyo's "Trastuzumab Deruxtecan" for advanced HER2-positive gastric cancer, and AbbVie’s "Risankizumab" for ulcerative colitis, showcasing significant advancements in treatment options [38][44]

Group 1 - The Hong Kong stock market is experiencing a downturn, with the innovative drug sector declining again, as evidenced by the Hong Kong Stock Connect Innovative Drug ETF (520880) falling by 1.5% [1][6] - Last week, the ETF accumulated a total decline of 3.2%, with over 236 million yuan in funds being used to buy on dips [1][6] - Major stocks in the sector are generally down, including CSPC Pharmaceutical Group down 3%, CanSino Biologics down nearly 4%, and China Biologic Products and Innovent Biologics both down over 2% [1][6] Group 2 - Multiple innovative drug business development (BD) transactions have been completed at the beginning of the year, indicating a positive trend for Chinese innovative drugs going overseas [8] - Key transactions include: 1) Rongchang Biologics granting AbbVie overseas rights for RC148 (PD-1/VEGF) dual antibody, receiving a $650 million upfront payment and up to $4.95 billion in milestone payments [8] 2) Haisco granting overseas rights for HSK39004 (PDE3/4) to AirNexis, receiving a $108 million upfront payment and up to $955 million in milestone payments [8] 3) Zai Lab granting AbbVie overseas rights for ZG006 (CD3xDLL3xDLL3 tri-antibody), receiving a $100 million upfront payment and milestone payments totaling $1.135 billion [8] 4) Yilian Biologics granting Roche overseas rights for YL201 (B7-H3ADC), with upfront and milestone payments reaching $570 million [8] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds are highlighted as high-elasticity investment tools, with the underlying index (Hang Seng Stock Connect Innovative Drug Select Index) offering three unique advantages [9] - The ETF has a 100% purity, excluding CXO, and fully covers innovative drug R&D companies [9] - The top ten innovative drug leaders account for over 73% of the ETF, showcasing the strength of the innovative drug sector [9][10]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with significant market potential anticipated for weight loss and diabetes treatments [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the potential of GLP-1 drugs [45] 4. Recent Industry Policies and News - Recent policies include the promotion of high-quality development in the pharmaceutical retail sector and the approval of numerous medical devices by the National Medical Products Administration [46][48]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Summary of Conference Call Industry Overview - The conference focused on updates and developments in the Chinese biopharmaceutical industry, particularly highlighting companies such as BeiGene, 3SBio, and Kelun-Biotech [1][10]. Key Company Insights BeiGene - BeiGene's BCL-2 inhibitor has been approved for sale in China and is expected to receive accelerated approval in the U.S. within the year [1]. - BCL-2 is viewed as a second growth driver for BeiGene, complementing its existing BTK inhibitors, which have shown rapid sales growth in the U.S. market [2]. - The company has a robust pipeline for solid tumors, with several candidates entering late-stage development, including treatments for breast cancer and other indications [3]. - BeiGene is anticipated to report its first annual profit, with expectations that its annual report may exceed forecasts [3]. 3SBio - Pfizer has outlined a global development plan for its drug 707, with five global Phase III trials expected to start by 2026, targeting various cancers [4]. - The trials include first-line treatments for colorectal cancer and non-small cell lung cancer [4]. Kelun-Biotech - Kelun-Biotech is expected to have a significant year with five products anticipated to be commercialized, three of which have already been included in the national medical insurance [5]. - The company has successfully commercialized its top two ADC products and is expected to see explosive growth following their inclusion in insurance [5]. Innovent Biologics - Innovent's Ivosidenib is expected to receive final approval from the FDA in Q4 of this year, with ongoing clinical trials for various cancers [6][7]. - The company is also preparing for the commercialization of its CAR-T product, which has already been approved domestically [8]. Rongchang - Rongchang has announced plans for three Phase III trials, including one for non-small cell lung cancer, which has received FDA approval [7][8]. Other Notable Mentions - Merck has initiated 16 global Phase III trials for its drug targeting various major indications, with data expected in the second half of the year [5]. - The conference highlighted the importance of clinical trial data releases for several companies, which are crucial for their long-term valuations [3][10]. Market Dynamics - The overall market for innovative drugs is currently experiencing a downturn, primarily due to internal funding shifts within the pharmaceutical sector [10]. - The high percentage of holdings in innovative and traditional pharmaceuticals (around 75%) has led to a reallocation of funds towards other sectors like AI healthcare and CROs [11]. - Despite the market's performance, the fundamental aspects of many companies remain strong, with ongoing clinical advancements and positive earnings expectations [11]. - The total amount of business development (BD) transactions in recent weeks has already reached 25% of last year's total, indicating a robust pace of international expansion [11]. Conclusion - The conference provided a comprehensive overview of the current state of the biopharmaceutical industry in China, highlighting significant advancements and the potential for growth among key players. The market dynamics suggest a temporary disconnect between stock performance and fundamental company health, indicating potential investment opportunities.